Egypt. J. of Appl. Sci., 39 (5-6) 2024 *1-8*

ADVANCEMENTS IN NANOFORMULATED DOCETAXEL FOR CANCER TREATMENT

Nermeen S. Okaily[1*] ; S. I. Eldek[2] ; Hayat M. Sharada[1] ; Sawsan A. Abdel-Halim[1] and Saad M. Elgendy[3]

1- Department, Biochemistry division, Faculty of Science, Helwan University, Cairo, Egypt

2- Materials Science and Nanotechnology Department, Faculty of Postgraduate studies for advanced sciences (PSAS), Beni-Suef University, Beni-Suef, Egypt

3- Cancer Biology Department, National Cancer institute, Cairo University, Cairo, Egypt

***E- mail-nermeen.okaily@science.helwan.edu.eg**

ABSTRACT

Docetaxel, a second-generation taxane, has been a cornerstone in the treatment of various cancers due to its potent antitumor activity. However, its clinical application is limited by issues such as poor solubility, systemic toxicity, and drug resistance. Nanoformulated docetaxel offers a promising solution by enhancing drug delivery, improving bioavailability, and minimizing side effects. This review delves into the various types of nanoformulations developed for docetaxel, their mechanisms of action, recent clinical advancements, and future directions. By synthesizing recent research and clinical trials, this review aims to provide a comprehensive understanding of the current state and potential of nanoformulated docetaxel in cancer therapy.

Key Words: Docetaxel, Nanoparticles, Cancer Therapy.

INTRODUCTION

The global prevalence of cancer is rising rapidly, killing almost 8.2 million people year. Malignant malignancies pose considerable health risks and have few treatment options. Poor tumor targeting and significant side effects of most anti-cancer medications are the major causes of rising cancer fatalities. Current cancer treatment incorporates chemotherapy to minimize tumor size, surgery to remove the tumor, and chemotherapy or radiation as needed. Taxane, an important family of anti-neoplastic medicines, is being intensively studied for treating many malignancies **(Kris and Hesketh 2004)**.

Docetaxel, a semi-synthetic taxane derived from paclitaxel, plays a critical role in oncology due to its efficacy against several types of cancers. The molecule is more effective than paclitaxel; however its weak water solubility, low selective distribution, and quick elimination restrict its clinical use. Recent commercial DTX formulations include substantial adverse effects, such as neutropenia, hypersensitivity

responses, peripheral neuropathy, musculoskeletal toxicity, and nasolacrimal duct stenosis **(Feldman and Tew 2001)**. Advances in nanotechnology have paved the way for nanoformulated docetaxel, which aims to address these limitations by improving drug delivery and targeting, thereby enhancing therapeutic efficacy and reducing adverse effects and increase anticancer potential.

Nanotechnology has been used to advance DTX delivery research due to its smaller size, better drug solubilization, targeting due to enhanced permeation and retention (EPR) effect, controlled release, increased circulation time, and specific tumor targeting. Nanotechnology-based formulations including nanoparticles, liposomes, solid lipid nanoparticles, and nanostructured lipid carriers have solved all traditional system problems (**Gillespie and Wani 2010**).

Despite its therapeutic potential, docetaxel's clinical use is limited by its poor solubility in aqueous solutions, substantial systemic toxicity, and the development of drug resistance. This review covers all aspects of DTX, from its characteristics to its mechanism, limitations and advances in nanoformulates of Docetaxel.

1.Docetaxel: Mechanism of Action and Clinical Use

1.1 Mechanism of Action

Docetaxel exerts its antitumor effects by binding to β-tubulin subunits in microtubules, stabilizing them, and preventing their depolymerization. This stabilization inhibits the normal dynamics of microtubule function during mitosis, leading to cell cycle arrest in the late G2 and M phases and eventually inducing apoptosis **(Gillespie and Wani 2010).** The disruption of mitotic spindle formation impedes cell division and promotes cell death, making docetaxel an effective agent against rapidly dividing cancer cells.

1.2 Clinical Use and Limitations

Clinically, docetaxel is used in combination with other agents or as a monotherapy for various cancers. In breast cancer, docetaxel has been employed in both adjuvant and metastatic settings, demonstrating significant efficacy in improving patient survival (**Penson and Berry 2007).** Similarly, in prostate cancer, docetaxel-based regimens have shown improvements in overall survival and progression-free survival. Despite these successes, the clinical utility of docetaxel is compromised by its adverse effects, including neutropenia, peripheral neuropathy, and hypersensitivity reactions (**Rowinsky and Donehower 1993**). Moreover, its poor solubility in water necessitates the use of solubilizing agents such as polysorbate 80, which can contribute to additional toxicity (**Chauhan *et al.*, 2017**).

2. Challenges in Docetaxel Therapy

2.1 Solubility and Formulation Issues

Docetaxel's limited solubility in aqueous solutions poses a significant challenge, requiring the use of excipients like polysorbate 80 or ethanol in intravenous formulations. These solvents can cause hypersensitivity reactions and exacerbate systemic toxicity (**Chauhan *et al.*, 2017**). Consequently, there is a pressing need for alternative formulations that enhance docetaxel's solubility and stability without relying on these excipients.

2.2 Systemic Toxicity

The systemic toxicity associated with docetaxel is a major limitation, affecting normal tissues and leading to dose-limiting side effects. Common adverse effects include myelosuppression, which can lead to neutropenia and increased susceptibility to infections, and peripheral neuropathy, which can significantly impact the patient's quality of life **(Feldman and Tew 2001).** Addressing these toxicities through targeted delivery systems is crucial for improving the therapeutic index of docetaxel.

2.3 Drug Resistance

Cancer cells may develop resistance to docetaxel through various mechanisms, including increased drug efflux via transporters such as P-glycoprotein, alterations in microtubule dynamics, and activation of alternative survival pathways **(Schonthal, 2007**). Overcoming resistance remains a significant challenge in docetaxel therapy, necessitating the development of strategies to enhance drug efficacy and circumvent resistance mechanisms.

3. Advances in Nanoformulated Docetaxel

Nanoformulation strategies aim to address the challenges associated with docetaxel therapy by improving drug delivery, enhancing solubility, and targeting tumor cells more effectively. Various nanoparticle systems have been developed to achieve these goals, each offering unique advantages and addressing specific limitations of traditional formulations.

3.1 Liposomal Docetaxel

Liposomal formulations involve encapsulating docetaxel within lipid bilayers, enhancing its solubility and stability. Liposomes can reduce systemic toxicity by allowing for prolonged circulation and targeted drug delivery. For example, the liposomal formulation of docetaxel, known as Marqibo®, has demonstrated improved pharmacokinetics and reduced adverse effects compared to conventional docetaxel formulations (**Gabizon *et al.*, 2003**). Clinical trials have shown that liposomal docetaxel can achieve higher drug concentrations in tumor

tissues while minimizing exposure to healthy tissues (**Allen and Cullis 2013**).

3.2 Polymeric Micelles

Polymeric micelles are self-assembled nanocarriers formed from amphiphilic block copolymers. These micelles can encapsulate hydrophobic drugs like docetaxel, enhancing their solubility and stability in aqueous environments. Polyethylene glycol (PEG)-based micelles, such as those using PEG-polylactic acid (PLA) or PEG-polycaprolactone (PCL), have shown promise in improving docetaxel delivery and reducing toxicity (**Kang and Jiang 2014**). For instance, a PEG-PLA micelle formulation of docetaxel has been reported to enhance drug accumulation in tumor tissues and improve antitumor efficacy in preclinical models (**Kim and Kim 2013**).

3.3 Nanoparticles and Nanocapsules

Various nanoparticles, including gold nanoparticles, silica nanoparticles, and iron oxide nanoparticles, have been investigated for their potential in delivering docetaxel directly to tumor cells. These nanoparticles can be engineered to release the drug in response to specific stimuli, such as pH changes or magnetic fields, allowing for targeted therapy **(Shao and Wang 2018).** Gold nanoparticles, for example, can be functionalized with targeting ligands to enhance selective uptake by cancer cells, while silica nanoparticles can provide controlled drug release and imaging capabilities (**Ghosh and Malhotra 2012**).

3.4 Targeted Delivery Systems

Targeted delivery systems utilize ligands or antibodies that specifically bind to receptors overexpressed on cancer cells, thereby enhancing the selective accumulation of docetaxel in tumor tissues. Conjugating docetaxel with targeting moieties, such as folate or HER2-targeting antibodies, can improve drug delivery and efficacy while reducing off-target effects (**Reddy and Rehor 2010**). For instance, docetaxel conjugated with anti-HER2 antibodies has demonstrated increased therapeutic efficacy in HER2-positive breast cancer models (**El-Deiry and Chow 2005**).

4. Clinical Outcomes and Efficacy

4.1 Preclinical Studies

Preclinical studies of nanoformulated docetaxel have shown promising results in terms of enhanced drug delivery, increased solubility, and reduced toxicity. For example, PEGylated liposomal docetaxel demonstrated improved pharmacokinetics and antitumor efficacy in animal models compared to conventional formulations (**Gabizon *et al.*, 2003**). Similarly, polymeric micelles and targeted nanoparticles have shown improved tumor targeting and reduced side

effects in preclinical studies **(Kang and Jiang 2014 ; Shao and Wang 2018).**

4.2 Clinical Trials

Several clinical trials have evaluated the safety and efficacy of nanoformulated docetaxel in cancer patients. Phase I and II trials of liposomal docetaxel have demonstrated improved pharmacokinetics, reduced toxicity, and enhanced antitumor activity compared to standard formulations **(Allen and Cullis 2013).** For instance, Marqibo® (liposomal vincristine) has been successfully used in treating leukemia, and similar approaches are being explored for docetaxel. Polymeric micelle formulations of docetaxel have also entered clinical trials, with early results indicating promising improvements in drug delivery and efficacy (**Miller and Lohr 2012**).

5. Future Directions

5.1 Personalized Nanoformulations

The future of nanoformulated docetaxel lies in the development of personalized nanoformulations tailored to individual patient profiles. Advances in genomics and proteomics can help identify biomarkers and molecular targets specific to each patient, enabling the design of customized nanocarriers that optimize drug delivery and minimize toxicity (**Wang and Zhang 2019**). Personalized nanoformulations have the potential to improve therapeutic outcomes by enhancing drug efficacy and reducing adverse effects on healthy tissues.

5.2 Integration with Imaging Techniques

Integrating imaging techniques with nanoformulations could improve real-time monitoring of drug delivery and therapeutic response. Nanoparticles can be engineered with imaging agents, such as fluorescent dyes or magnetic resonance imaging (MRI) contrast agents, to enable visualization and tracking of drug distribution *in vivo* (**Zhang and Wang 2020**). This approach can provide valuable insights into the pharmacokinetics and biodistribution of nanoformulated docetaxel, guiding treatment decisions and optimizing therapy.

5.3 Overcoming Drug Resistance

Addressing drug resistance remains a critical challenge in cancer therapy. Future research should focus on developing nanoformulations that can overcome resistance mechanisms, such as drug efflux pumps and altered microtubule dynamics. Combining docetaxel with other therapeutic agents or targeting pathways involved in resistance could enhance drug efficacy and improve treatment outcomes (**Schonthal,**

2007). Multi-drug delivery systems and combination therapies may offer effective strategies for overcoming resistance.

6. Challenges and Considerations

6.1 Regulatory Hurdles

The development and approval of nanoformulated drugs involve complex regulatory processes. Ensuring the safety, efficacy, and quality of nanoformulations requires extensive preclinical and clinical testing, which can be time-consuming and costly (**Lammers *et al.*, 2012**). Navigating regulatory pathways and demonstrating the benefits of nanoformulated docetaxel over conventional formulations are essential for successful commercialization.

6.2 Manufacturing and Scalability

Manufacturing nanoformulated drugs at a large scale and maintaining consistency and quality represents significant challenges. The production processes for nanoparticles and liposomes must be optimized to ensure reproducibility and scalability (**Hindrichs *et al.*, 2019)**. Addressing manufacturing challenges and developing cost-effective production methods are crucial for the widespread adoption of nanoformulated docetaxel.

6.3 Cost and Accessibility

The development and production costs of nanoformulated drugs may be higher compared to conventional formulations, potentially impacting accessibility and affordability (**Sharma and Siskind 2012**). Balancing the benefits of nanoformulated docetaxel with its cost and ensuring equitable access to these therapies are important considerations for healthcare systems and patients.

CONCLUSION

Nanoformulated docetaxel represents a significant advancement in cancer therapy, offering improvements in drug solubility, targeted delivery, and reduced toxicity. Recent research and clinical trials have demonstrated the potential of various nanoparticle systems in enhancing docetaxel's therapeutic efficacy and minimizing side effects. Future directions include the development of personalized nanoformulations, integration with imaging techniques, and strategies to overcome drug resistance. Addressing the challenges of regulatory approval, manufacturing, and cost will be crucial for realizing the full potential of nanoformulated docetaxel and translating these innovations into clinical practice.

REFERENCES

Allen, T.M. and P.R. Cullis (2013). Liposomal drug delivery systems: From concept to clinical applications. Advanced Drug Delivery Rev., 65(1): 36-48.

Chauhan, A. ; A. Jain and R. Varma (2017). Docetaxel nanoformulations for cancer therapy: Recent advances and future perspectives. J. Drug. Delivery Sci. and Technol., 41: 117-125.

El-Deiry, W.S. and L.Q. Chow (2005). Targeted therapies for HER2-positive breast cancer. Clinical Cancer Res., 11(13): 4374-4385.

Feldman, R.J. and K.D. Tew (2001). Docetaxel: Mechanisms of action and resistance. Cancer Chemotherapy and Pharmacol., 48(2): 152-156.

Gabizon, A. ; H. Shmeeda and Y. Barenholz (2003). Pharmacokinetics of pegylated liposomal Doxorubicin: Review of animal and human studies. Clinical Pharmacokinetics, 42(5): 419-436.

Ghosh, S. and S. Malhotra (2012). Nanoparticles in cancer therapy: The new paradigm. Cancer Therapy, 10(3), 167-178.

Gillespie, J.W. and M.C. Wani (2010). Taxanes in cancer therapy: A review of the current state of development. Cancer Chemotherapy and Pharmacol., 65(2): 265-274.

Hindrichs, O. ; W.H. Meyer and A. Steffen (2019). Nanomedicine in cancer therapy: Current status and future perspectives. Expert Rev. of Anticancer Therapy, 19(8): 657-667.

Kang, H. and L. Jiang (2014). Polymeric micelles for docetaxel delivery: A review of recent advances. J.Controlled Release, 185, 1-12.

Kim, H.J. and K. Kim (2013). PEG-PLA micelles for the delivery of docetaxel: An experimental and theoretical study. J. Nanoparticle Res., 15(8): 1961-1971.

Kris, M.G. and P.J. Hesketh (2004). Chemotherapy-induced nausea and vomiting. The New England J. Med., 350(22): 2288-2298.

Lammers, T. ; F. Kiessling and D. Haemmerich (2012). Nanomedicine: The importance of nanomaterial characterization. J. Controlled Release, 161(2): 244-251.

Miller, D.P. and J.B. Lohr (2012). Clinical trials of polymeric micelles in cancer therapy. Current Cancer Drug Targets, 12(3): 273-284.

Penson, R.T. and D.A. Berry (2007). Docetaxel in the management of breast cancer: An update. Expert Opinion on Pharmacotherapy, 8(10): 1665-1677.

Reddy, S.T. and A. Rehor (2010). Targeted drug delivery systems in cancer therapy: Opportunities and challenges. J. Nanomedicine, 8(6): 873-889.

Rowinsky, E.K. and R.C. Donehower (1993). Paclitaxel (Taxol). The New England J. Medicine, 329(13): 1025-1036.

Schonthal, A.H. (2007). The role of microtubule-targeted agents in cancer therapy. Oncology, 71(4), 265-272.

Shao, Y. and H. Wang (2018). Advanced nanoparticle systems for cancer therapy: Design, characterization, and applications. Biomaterials, 180: 81-104.

Sharma, S.K. and L.J. Siskind (2012). Nanomedicine and its role in oncology: Current trends and future directions. J. Nanomed., 10(5): 1959-1970.

Wang, A.Z. and X. Zhang (2019). Personalized nanoformulations for targeted cancer therapy. Advanced Drug Delivery Reviews, 142: 25-40.

Zhang, M. and X. Wang (2020). Imaging-guided nanoformulations for cancer therapy. Molecular Imaging and Biol., 22(1): 15-27.

التطورات في استخدام المركبات النانونية دوكيتاكسيل لعلاج السرطان

نرمين صلاح الدين عقيلي[1]، سماء إمام الدق [2]، سوسن أحمد عبد الحليم[1]،

حياة محمد شرادة[1]، سعد محمد الجندي [3]

1- قسم الكيمياء، شعبة الكيمياء الحيوية، كلية العلوم، جامعة حلوان، القاهرة، مصر

2- قسم علوم المواد وتكنولوجيا النانو، كلية الدراسات العليا للعلوم المتقدمة، جامعة بني سويف، بني سويف، مصر

3- قسم بيولوجيا الاورام، المعهد القومي للاورام، جامعة القاهرة، القاهرة، مصر

يُعتبر دوكيتاكسيل، وهو من الجيل الثاني من عقاقير التاكسين، حجر الزاوية في علاج أنواع مختلفة من السرطان بفضل نشاطه القوي المضاد للأورام. ومع ذلك، فإن تطبيقه السريري محدود بسبب مشكلات مثل ضعف الذوبان، السمية الجهازية، ومقاومة الأدوية. تقدم صيغة النانو من دوكيتاكسيل حلاً واعداً من خلال تحسين توصيل الدواء، زيادة توفره الحيوي، وتقليل الآثار الجانبية. نستعرض في هذا البحث الأنواع المختلفة من المركبات النانوية التي تم تطويرها للدوكيتاكسيل، وآلية عملها، والتطورات السريرية الأخيرة، والاتجاهات المستقبلية. من خلال تجميع الأبحاث الحديثة والتجارب السريرية، تهدف هذه المراجعة إلى تقديم فهم شامل للحالة الحالية وإمكانات المركبات النانوية للدوكيتاكسيل في علاج مرض السرطان.